Bradlee Heckman

IBradlee L. Heckmann is an American biologist and neuroimmunologist who works at the Byrd Alzheimer’s Center and the University of South Florida’s Health Neuroscience Institute (USF). He is also Assistant Professor of molecular medicine at Morsani College of Medicine (USF). Dr. Bradlee Heckmann’s current research focuses on modulating neuroinflammation as therapeutic targeting to treat neurodegenerative diseases, including Alzheimer’s and the role of the machinery of autophagy in this context. In addition to his academic positions, Heckmann is co-founder and CSO of Asha Therapeutics, a biotech pharmaceutical company, based in Tampa (Florida) that explores novel therapies for neurodegeneration and neuro-oncology for a variety of diseases including Parkinson’s, Alzheimer’s and myalgic encephalomyelitis/chronic fatigue syndrome/long COVID.